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Abstract 28 
AIMS/HYPOTHESIS: Protein-tyrosine phosphatase 1B (PTP1B) is a key negative regulator 29 
of insulin signalling. Hepatic PTP1B deficiency, using the Alb-Cre promoter to drive Ptp1b 30 
deletion from birth, improves glucose homeostasis, insulin sensitivity and lipid metabolism. 31 
The aim of this study was to investigate the therapeutic potential of decreasing liver-PTP1B 32 
levels in obese and insulin resistant adult mice.  33 
METHODS: To investigate this, inducible-Ptp1b liver-specific knockout mice were 34 
generated using SA-CRE-ER
T2
 mice crossed with Ptp1b floxed (Ptp1b
fl/fl
) mice. Mice were 35 
fed a high-fat diet (HFD) for 12 weeks to induce obesity and insulin resistance. Tamoxifen 36 
was administered within HFD to induce liver-specific deletion of Ptp1b (SA-Ptp1b
-/-
 mice). 37 
Body weight, glucose homeostasis, lipid homeostasis, serum adipokines, insulin signalling 38 
and ER stress were examined.  39 
RESULTS: Despite no significant change in body weight relative to HFD-fed Ptp1b
fl/fl 40 
control mice, HFD-fed SA-Ptp1b
-/-
 mice exhibited a reversal of glucose intolerance as 41 
determined by improved glucose and pyruvate tolerance tests, decreased fed and fasted blood 42 
glucose and insulin levels, lower HOMA-IR, circulating leptin, serum and liver triglycerides, 43 
serum free fatty acids and decreased HFD-induced ER stress. This was associated with 44 
decreased glycogen synthase, PERK, eIF2α and JNK2 phosphorylation and decreased 45 
expression of Pepck.  46 
CONCLUSIONS/INTERPRETATION: Inducible liver-specific Ptp1b knockdown  47 
reverses glucose intolerance and improves lipid homeostasis in HFD-fed obese and insulin 48 
resistant adult mice. This suggests that knockdown of liver-PTP1B in subjects that are 49 
already obese/insulin resistant may have relatively rapid, beneficial therapeutic effects.  50 
KEY WORDS: Liver, PTP1B, Phosphatase, NAFLD, Disease, Glucose, Lipid, Insulin, 51 
Leptin, ER Stress.
 52 
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Abbreviations 53 
ER   Endoplasmic reticulum 54 
GTT    Glucose tolerance test 55 
HFD   High-fat diet 56 
HOMA-IR  Homeostatic model assessment of insulin resistance 57 
IR   Insulin receptor 58 
JAK2   Janus kinase 2 59 
NAFLD  Non-alcoholic fatty liver disease 60 
PTP1B   Protein tyrosine phosphatase 1B 61 
 62 
Introduction 63 
Caloric excess and low physical activity are key drivers of rising obesity levels in Western 64 
society. Insulin resistance and obesity are associated with the development of cardiovascular 65 
disease, type 2 diabetes and cancer [1]. Insulin resistance leads to hyperglycaemia, caused by 66 
a decrease in insulin-dependent glucose uptake into peripheral tissues and diminished ability 67 
of insulin to suppress hepatic glucose production [2]. Insulin resistance is also associated with 68 
dyslipidemia [3] and non-alcoholic fatty liver disease (NAFLD), which is the most common 69 
liver disease across the world (20-35% of the population) [4]. It is distinguished by excess 70 
hepatic fat stores, in the absence of alcohol consumption [4]. Lifestyle factors such as 71 
nutrition and exercise can influence whether NAFLD is likely to progress to non-alcoholic 72 
steatohepatitis [4], which carries an increased risk of mortality [5]. This rising burden of 73 
metabolic disease requires the development of new therapeutic strategies [6]. 74 
    Protein tyrosine phosphatise 1B (PTP1B) is a non-receptor tyrosine phosphatase which is 75 
ubiquitously expressed in all insulin-responsive tissues [7]. PTP1B is a negative regulator of 76 
both insulin and leptin signalling, through its actions on the insulin receptor (IR) and Janus 77 
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kinase 2 (JAK2) [7]. Whole body Ptp1b
-/-
 mice have enhanced insulin sensitivity, increased 78 
phosphorylation of tyrosine residues on the IR and reduced adiposity on high-fat diet (HFD) 79 
[8, 9]. PTP1B antisense oligonucleotides were shown to effectively lower PTP1B levels in 80 
liver and fat, enhance insulin signalling, as well as decrease adiposity in ob/ob and db/db 81 
mice [10, 11]. Lipogenic genes were down-regulated in fat and liver, including diminished 82 
Pparγ gene expression in adipose tissue [12]. However, whether these positive effects were 83 
due to loss of PTP1B in the liver and/or adipose tissue or any other tissue(s) was unclear. 84 
Subsequently, tissue-specific Ptp1b knockout mice were generated to identify the specific 85 
tissues responsible for PTP1B’s effects on insulin sensitivity and lipid metabolism [2, 13, 14]. 86 
    Neuronal Ptp1b
-/-
 mice display decreased body mass, reduced food intake and enhanced 87 
energy expenditure on a high-fat diet (HFD) [13]. This is due, at least in part, to leptin 88 
hypersensitivity in these mice; PTP1B acts as a negative regulator of leptin signalling via its 89 
ability to dephosphorylate JAK2 on tyrosine sites Y1007/Y1008 and altering downstream 90 
STAT3 phosphorylation [15]. Adipocyte-specific Ptp1b deletion increases adipocyte size and 91 
serum levels of glucose and leptin, without affecting body weight [6]. Muscle-specific and 92 
liver-specific deletion of Ptp1b has no effect on body weight, but in contrast to adipocyte-93 
Ptp1b deletion, improves peripheral insulin sensitivity and whole body glucose homeostasis 94 
[2, 14]. Liver-specific Ptp1b deletion also decreases serum triglyceride levels and lowers 95 
lipogenic gene expression in livers of mice fed HFD (Srebp1c, Srebp1a and Fas). It is 96 
thought that this may be due to decreased endoplasmic reticulum (ER) stress response 97 
induction observed in these mice [16, 17].  98 
    Specifically targeting liver-PTP1B appears to be an attractive drug therapy for treatment of 99 
metabolic syndrome, as it not only improves whole body insulin sensitivity and glucose 100 
homeostasis but also decreases lipid deposition in the liver, thus potentially limiting the 101 
development of co-morbidities such as NAFLD.  102 
5 
 
    Previous studies have examined beneficial effects of liver PTP1B deficiency using Alb-Cre 103 
mice which induces hepatocyte-Ptp1b deletion from birth [2]. The aim of this study was to 104 
investigate whether inhibiting liver-PTP1B in adult mice with already established obesity and 105 
insulin resistance could reverse the phenotype and therefore present a novel treatment for 106 
insulin resistance and type 2 diabetes. To do this, we used a tamoxifen-dependent Cre 107 
recombinase system under the control of the serum albumin promoter to target Ptp1b 108 
specifically in liver.  109 
 110 
Materials and Methods 111 
    Ethics statement. All animal procedures were approved by the University of Aberdeen 112 
Ethics Review Committee Board and performed under a project license approved by the 113 
Home Office under the Animals (Scientific Procedures) Act 1986 (PPL60/3951).  114 
    Animal studies. Ptp1b
fl/fl
 mice and SA-CRE-ER
T2
 mice expressing Cre-ER
T2
 recombinase 115 
under the control of the serum albumin promoter were described previously [18, 19]. 116 
Tamoxifen treatment of mice efficiently induces Cre-mediated recombination of LoxP 117 
flanked (floxed) alleles in hepatocytes but not in other cell types or tissues [19]. SA-Cre-ER
T2
 118 
mice, when crossed to Ptp1b
fl/fl 
mice, provide a tool to temporally control targeted 119 
mutagenesis in hepatocytes. Tamoxifen administration induces a liver-specific deletion of 120 
Ptp1b (hereafter termed SA-Ptp1b
-/-
). DNA extraction and genotyping for the Ptp1b floxed 121 
allele and the presence of Cre-ER
T2
 by PCR were performed as described previously [18]. 122 
Mice studied were age-matched littermates, which were generated on a C57BL/6 123 
background. Mice were housed in groups, unless otherwise stated, and maintained at 22-24ºC 124 
on a 12-h light/dark cycle with free access to food and water. At weaning (~21 days), mice 125 
were placed on standard 3.4% fat chow pellet diet (Rat and Mouse Breeder and Grower, 126 
Special Diets Services, DBM, Scotland) or HFD (Adjusted Calories Diet, 55 % fat, Harlan 127 
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Teklad, USA) and weight was recorded every two weeks. The approximate fatty acid profile 128 
of Adjusted Calories Diet (% total fat) was 28% saturated, 30% trans, 28% monounsaturated 129 
(cis) and 14% polyunsaturated (cis), as described previously [20]. For insulin signalling 130 
experiments, HFD-fed mice were fasted overnight (16 hours) and then injected 131 
intraperitoneally with saline or insulin (10 mU/g body weight) for 10 minutes. Tissues were 132 
dissected immediately post-cervical dislocation and frozen in liquid nitrogen.     133 
    Tamoxifen administration. To prepare tamoxifen, ethanol was added to make a 10 134 
mg/100 µl suspension. Sunflower seed oil was then added to prepare a 10 mg/ml solution. 135 
This was heated at 55˚C for 30 minutes. This mixture of tamoxifen, ethanol and sunflower oil 136 
was then incorporated into HFD (55% fat) at 0.7 mg tamoxifen/gram of food. A control HFD 137 
(55% fat) was simultaneously administered to a control group containing ethanol and 138 
sunflower oil only. Mice were fed the tamoxifen or control HFD for 28 days. 139 
    PTP1B activity assay. Tissue lysates were prepared in PTP lysis buffer (130 mmol/l 140 
NaCl, 20 mmol/l Tris (pH 7.5), 5 mmol/l EDTA, 1% Triton X-100 (v/v), 0.5% Nonidet P-40 141 
(v/v) containing protease inhibitors. PTP1B protein was immunoprecipitated using PTP1B 142 
antibody (Millipore) and protein G-sepharose beads. Beads were re-suspended in 60 µl of 143 
PTP assay buffer (100 mmol/l Hepes (pH 7.6), 2 mmol/l EDTA, 1 mmol/l DTT, 150 mmol/l 144 
NaCl, 0.5 mg/ml BSA) containing phosphoregulatory peptide (200 µmol/l). The reaction 145 
proceeded for 30 minutes at 30°C with constant shaking. The concentration of phosphate 146 
produced (µmol/l) was then measured by absorbance at 620 nm using biomol green reagent 147 
(Enzo Life Sciences) and phosphate standards. 148 
    Histology. Frozen tissues were embedded in OCT and sectioned by cryostat. Samples were 149 
stained in hematoxylin and eosin. Slides were visualised using a Zeiss Axioskop microscope 150 
(Carl Zeiss Microscopy, LLC, NY, USA) and imaged using AxioVision 4.8 digital image 151 
processing software (Carl Zeiss Microscopy, LLC, NY, USA).  152 
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    Serum analysis. Serum insulin and leptin (CrystalChem, Downers Grove, USA, Cat 153 
90080 Insulin/90030 Leptin) were determined by ELISA, following manufacturer’s 154 
instructions. TNFα, IL-6, MCP-1 and Resistin were determined by multiplex ELISA assay 155 
(MADKMAG-71K, Millipore), following manufacturer’s instructions. Serum glucose 156 
(glucose oxidase, Thermo Scientific, Cat TR1503) and serum triglycerides (Sentinel 157 
Diagnostics, Milan, Italy, Cat 17628 or Sigma, Cat TR0100) were determined using 158 
appropriate kits, following manufacturer’s instructions. Serum free fatty acids were 159 
determined using a non-esterified fatty acid (NEFA C) kit (Wako Chemicals, Virginia, USA, 160 
Cat 994-75409E). Alanine aminotransferase activity was determined using an alanine 161 
aminotransferase activity assay kit (BioVision, California, USA, Cat K752-100) to determine 162 
liver function and health. Glucose and insulin concentrations were used to calculate the 163 
homeostasis model assessment of insulin resistance (HOMA-IR), a reliable marker of insulin 164 
sensitivity [21], which is defined as: fasting glucose (mmol/l) X fasting insulin (mU/l)/22.5. 165 
Assays were measured with a Spectramax Plus 384 spectrophotometer (Molecular Devices, 166 
CA, USA).   167 
    Liver triglycerides. ~100 mg pieces of liver were cut and weighed using analytical scales. 168 
1 ml PBS was added to each tube and homogenised. Samples were centrifuged for 15 seconds 169 
at room temperature. The top layer was resuspended with gentle shaking. The supernatant 170 
was transferred (without disturbing the pellet) to new 1.5 ml tubes. Triglycerides were then 171 
assayed using a kit, following manufacturer’s instructions (Sentinel Diagnostics, Milan, Italy, 172 
Cat 17628). 173 
    Glycogen determination. Two ~20 mg pieces of liver were cut and placed into 2 ml tubes. 174 
500 µl 2 mol/l HCL was added to half of the samples and 500 µl 2 mol/l NaOH (to control 175 
for free glucose) was added to the other half. All samples were heated for 2 h at 95°C. 500 µl 176 
2 mol/l NaOH was added to each tube containing HCL and 500 µl 2 mol/l HCL was added to 177 
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each tube containing NaOH for neutralization. Tubes were vortexed and centrifuged for 1 178 
min. Samples were diluted 1:50 in equal volumes of HCL and NaOH. 10 µl of diluted 179 
samples were used for the assay. 150 µl of hexokinase reagent (Sigma) was added to each 180 
well and incubated for 10 min at room temperature. The assay was measured at 340 nm with 181 
a Spectramax Plus 384 spectrophotometer (Molecular Devices, CA, USA).   182 
    Glucose and pyruvate tolerance tests. For glucose tolerance tests, mice were 183 
intraperitoneally injected, following a 16-hour fast, with 1.5-2 mg/g (1.5 mg for HFD-fed and 184 
2 mg for mice on chow diet) body weight glucose. For pyruvate tolerance tests, mice were 185 
injected with 1.5 mg/g pyruvate. Tail blood glucose values were measured using glucometers 186 
(AlphaTRAK, Berkshire, UK) immediately before and at 15, 30, 60, and 90 or 120 min post-187 
injection. 188 
    Immunoblotting. Tissue lysates were prepared in RIPA buffer containing fresh sodium 189 
orthovanadate and protease inhibitors, as described previously [22]. Proteins were separated 190 
by 4-12% SDS-PAGE and transferred to nitrocellulose membranes. Immunoblots were 191 
performed using antibodies from Cell Signaling (Cell Signaling by NEB, Hitchin, UK) 192 
(unless stated otherwise) against PTP1B (Millipore), Beta-Actin (Thermo Scientific), SHP2 193 
(Santa Cruz), pGS S641, pGSK3α/β S21/S9, pIR Y1162/63 (Invitrogen), pIR Y1158 194 
(Invitrogen), pAkt/PKB S473, pERK1/2 MAPK T202/Y204, pAkt/PKB T308, p-FRAP/p-195 
mTOR S2448 (Santa Cruz), pS6 ribosomal protein S235/236, pPERK T980, peIF2α S51, 196 
pSAPK/JNK T183/Y185, ERK2 and total Akt/PKB (Santa Cruz). Immunoblots were 197 
developed using horseradish peroxidase-conjugated secondary antibodies, visualized using 198 
enhanced chemiluminescence, and quantified by densitometry scanning with Image J or 199 
Bio1D software (PeqLab, Fareham, UK).  200 
    Gene expression analysis. Total RNA was isolated from mouse liver and epididymal 201 
adipose tissue using TRI Reagent (Ambion, Warrington UK), according to the 202 
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manufacturer’s protocol. First strand cDNA was synthesized from 1 µg of total RNA 203 
employing the Bioline Bioscript™ Pre-amplification System and oligo(dT)12-18. Two (2) μl of 204 
diluted cDNA (1:10) was used to amplify target genes by real-time RT-PCR (10 μl), using 205 
GoTaq qPCR Master Mix (Promega, Southampton, UK). The Roche LightCycler® 480 206 
System (Roche Diagnostics, Burgess Hill, UK) was used for analysis. Relative gene 207 
expression was calculated using the comparative Ct (2−ΔΔCt) method. A geometric mean of 208 
three commonly used reference genes; hypoxanthine-guanine phosphoribosyltransferase 209 
(Hprt), 18S ribosomal RNA (18S) and Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) 210 
was used to normalise data. A geometric mean of the relative copy numbers of mouse PCRs 211 
were followed by melting curves (70-95°C).  212 
    Data analysis. Data are expressed as mean ± SEM and n represents the number of mice or 213 
biological replicates. Statistical analyses were performed using one-way ANOVA with 214 
Tukey’s multiple comparison post-tests, repeated measures two-way ANOVA with 215 
Bonferroni multiple comparisons post-tests, one tailed t-tests or two-tailed Student’s t-tests, 216 
as appropriate. The critical alpha level (P) was set at 0.05. P < 0.05 was considered 217 
statistically significant. GraphPad Prism 5 statistical software was used for analyses. 218 
 219 
Results 220 
Inducible liver-specific Ptp1b knockdown improves glucose homeostasis. Body weight 221 
(Figure 1) was comparable between HFD-fed SA-Ptp1b
-/-
 and HFD-fed Ptp1b
fl/fl 
control mice 222 
throughout the study and ~50% decrease in PTP1B levels was achieved at 4- and 12-weeks 223 
post-tamoxifen treatment in HFD-fed SA-Ptp1b
-/-
 mice (Figure 1b and c, respectively). 224 
PTP1B activity was also ~20% lower in HFD-fed SA-Ptp1b
-/-
 mice compared with HFD-fed 225 
Ptp1b
fl/fl 
control mice (Figure 1d). Considering that PTP1B activity was ~40% lower in Alb-226 
Ptp1b
-/-
 mice (which have Ptp1b deletion in the liver from birth) (Figure 1d), this would be 227 
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consistent with 50% deletion at the protein level. As expected from other studies, tamoxifen 228 
treatment caused ~20% body weight loss in both groups of mice, which returned to pre-229 
tamoxifen levels on HFD (Figure 1). An outline of the experimental design is shown in 230 
Figure 1. As expected, HFD-fed SA-Ptp1b
-/-
 mice displayed no differences in glucose 231 
tolerance in comparison to Ptp1b
fl/fl 
mice prior to tamoxifen treatment, on chow or HFD 232 
(Figure 2a and b). Importantly, HFD-feeding induced glucose intolerance in both groups of 233 
mice, as evidenced by increased area under the curve in both groups (Figure 2d). After 234 
tamoxifen treatment, which induced PTP1B knockdown in SA-Ptp1b
-/-
 mice only (Figure 1b 235 
and c), HFD-fed SA-Ptp1b
-/-
 mice displayed a significantly improved response to glucose 236 
challenge and a reversal of glucose intolerance to chow-diet feeding levels (Figure 2a, c and 237 
d). Furthermore, fed and fasted serum glucose levels were lower in HFD-fed SA-Ptp1b
-/-
 mice 238 
compared with HFD-fed Ptp1b
fl/fl
 control mice, at 4- and 12-weeks post-tamoxifen treatment 239 
(Figure 2f and g). Fed serum insulin levels tended to be lower in SA-Ptp1b
-/-
 mice, although 240 
this did not reach significance (Figure 2h). However, fasting serum insulin levels were 241 
significantly lower at 4-weeks post-tamoxifen treatment in HFD-fed SA-Ptp1b
-/-
 mice 242 
compared with HFD-fed Ptp1b
fl/fl
 controls (Figure 2i). Importantly, HOMA-IR, which 243 
represents an index of insulin resistance, was significantly lower in HFD-fed SA-Ptp1b
-/-
 244 
mice, at 4- and 12-weeks post-tamoxifen treatment (Figure 2j).  245 
    Inducible liver-specific Ptp1b knockdown improves lipid homeostasis. Hematoxylin 246 
and eosin staining revealed a high level of inter-animal variability when examining lipid 247 
deposition in livers of HFD-fed SA-Ptp1b
-/-
 and Ptp1b
fl/fl
 mice (Figure 3a). We therefore also 248 
assessed total liver triglyceride levels, which revealed that liver triglycerides were 249 
significantly lower in the livers of HFD-fed SA-Ptp1b
-/-
 mice compared with HFD-fed 250 
Ptp1b
fl/fl
 controls (Figure 3b). There were no significant differences between groups in 251 
alanine aminotransferase activity (Figure 3c). Fed serum free-fatty acids were significantly 252 
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decreased at 4- and 12-weeks post-tamoxifen treatment in HFD-fed SA-Ptp1b
-/-
 mice 253 
compared with Ptp1b
fl/fl 
controls (Figure 3d). HFD-fed SA-Ptp1b
-/-
 mice also displayed 254 
significantly lower fasting serum free-fatty acids at 12-weeks post-tamoxifen treatment 255 
(Figure 3e). Fed and fasted serum triglycerides were significantly decreased at both 4- and 256 
12-week post-tamoxifen treatment compared with the starting pre-tamoxifen levels in HFD-257 
fed SA-Ptp1b
-/-
 mice only (Figure 3f and g). Moreover, both fed and fasted serum leptin 258 
levels were significantly lower at 4 weeks post-tamoxifen treatment in HFD-fed SA-Ptp1b
-/-
 259 
mice compared with HFD-fed Ptp1b
fl/fl
 control mice (Figure 3h and i). Furthermore, IL-6, 260 
MCP-1, Resistin and TNFα were measured in Ptp1bfl/fl control and SA-Ptp1b-/- mice in the 261 
fasted state (Table 2). SA-Ptp1b
-/-
 mice displayed lower IL-6 at 12-weeks post-tamoxifen 262 
compared with Ptp1b
fl/fl 
control mice (P = 0.059; two-tailed t-test), whilst MCP-1 was 263 
increased in SA-Ptp1b
-/-
 mice at 4-weeks post-tamoxifen compared with Ptp1b
fl/fl 
control 264 
mice. Resistin was not different between groups at any time point (Table 2) and TNFα 265 
concentrations were below the level of detection of the mouse multiplex ELISA (data not 266 
shown).     267 
    Inducible liver-specific Ptp1b knockdown improves suppression of hepatic 268 
gluconeogenesis. To assess if most of the improvements in glucose homeostasis were due to 269 
improvements in suppression of hepatic gluconeogenesis, we performed a pyruvate tolerance 270 
test. HFD-fed SA-Ptp1b
-/-
 mice displayed a significantly improved response to pyruvate 271 
challenge following overnight fasting compared with HFD-fed Ptp1b
fl/fl 
controls (Figure 2e). 272 
This is consistent with increased insulin-induced dephosphorylation of glycogen synthase at 273 
both 4- and 12-weeks post-tamoxifen treatment (Figure 4 a, b, c and d). Liver glycogen 274 
content was unaltered between SA-Ptp1b
-/-
 and Ptp1b
fl/fl
 control mice (5.97 ± 3.41 vs. 8.32 ± 275 
2.93 µg/mg, respectively). Surprisingly, components of the classical insulin signalling 276 
pathway were unchanged with liver-Ptp1b knockdown at either 4- or 12-week post-tamoxifen 277 
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(Figure 4a, b and e). Furthermore, insulin signalling in muscle and epididymal WAT was 278 
comparable between SA-Ptp1b
-/-
 and Ptp1b
fl/fl
 control mice (Figure 4f and g).  279 
    Inducible liver-specific Ptp1b knockdown is associated with decreased expression of 280 
liver gluconeogenic genes. To assess the mechanism(s) behind improvements in whole body 281 
glucose and lipid homeostasis, we analysed expression of genes involved in gluconeogenesis 282 
and lipogenesis. Consistent with the physiological data from pyruvate tolerance tests (Figure 283 
2e) and signalling data (Figure 4a, b, c and d), HFD-fed SA-Ptp1b
-/-
 mice displayed a 284 
decrease in gluconeogenic markers in comparison to HFD-fed Ptp1b
fl/fl 
control mice, as 285 
evidenced by decreased liver gene expression levels of Pepck (Table 1). Moreover, Ppary 286 
was significantly decreased in these mice (Table 1). Furthermore, Hmgcs1 was increased in 287 
HFD-fed SA-Ptp1b
-/-
 mice compared to HFD-fed Ptp1b
fl/fl 
control mice (Table 1). HFD-fed 288 
SA-Ptp1b
-/-
 mice exhibited unaltered lipogenic gene expression in liver or epididymal white 289 
adipose tissue compared to Ptp1b
fl/fl 
control mice (Table 1). Lipolytic and adipokine gene 290 
expression levels were unaltered between the groups in epididymal white adipose tissue 291 
(Table 1).  292 
    Inducible liver-specific Ptp1b knockdown decreases ER stress. At the gene expression 293 
level there was a significant decrease in Grp94 in HFD-fed SA-Ptp1b
-/-
 mice compared to 294 
HFD-fed Ptp1b
fl/fl 
control mice (Table 1). At the protein level, HFD-fed SA-Ptp1b
-/-
 mice 295 
exhibited significantly lower phosphorylation of PERK, eIF2α and JNK2 when compared to 296 
Ptp1b
fl/fl 
control mice (Figure 5a, b, c and d).  297 
 298 
Discussion 299 
There is a growing body of evidence to suggest that PTP1B inhibitors hold great promise for 300 
treatment of type 2 diabetes as well as cancer [3, 4, 8, 16-18, 22-30]. Numerous mouse and 301 
human studies have demonstrated that decreasing PTP1B in various tissues including muscle, 302 
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liver and the brain leads to a multitude of beneficial effects [17, 18, 22, 31]. Liver-specific 303 
Ptp1b knockout in mice (Alb-Ptp1b
-/-
) led to improved glucose homeostasis and decreased 304 
levels of triglycerides independent of changes in body weight [17]. However, previous 305 
studies investigated mice with a knockout of Ptp1b from birth and have therefore examined 306 
the effects of Ptp1b deletion as a preventative of type 2 diabetes, not as a treatment in the 307 
already obese and insulin resistant states. Using a tamoxifen-dependent Cre recombinase 308 
system, we now demonstrate that decreasing liver-PTP1B by ~50% in obese and insulin 309 
resistant adult mice, leads to a reversal of glucose intolerance and improvements in lipid 310 
homeostasis, and that these effects are manifested within just a matter of weeks post hepatic-311 
Ptp1b knockdown.  312 
    As expected, and reported by others, oral tamoxifen treatment caused a transient decrease 313 
in body weight in both groups of mice [32-34]. As with other mouse models of Ptp1b-314 
specific deletion [17, 22], body weight of the inducible liver-specific Ptp1b knockout mice 315 
did not differ from control mice. Ptp1b-knockdown decreased PTP1B protein levels by ~50% 316 
and PTP1B activity by ~20% in livers from SA-Ptp1b
-/-
 mice. 50% knockdown is less than 317 
was observed previously in livers from Alb-Ptp1b
-/-
 mice (achieving ~80% hepatic Ptp1b 318 
deletion and ~40% activity inhibition) [16, 17]. It has recently been reported that different 319 
Cre lines display different degrees of efficiency and specificity [35]. In addition to 320 
differences amongst Cre mice, different floxed gene loci were shown to display a range of 321 
sensitivity to recombination when using different Cre lines [35]. However, a 50% decrease in 322 
PTP1B levels is physiologically relevant, as PTP1B inhibitors would only be expected to 323 
achieve approximately these levels [24]. 324 
    In agreement with previous studies, glucose homeostasis is improved in SA-Ptp1b
-/-
 mice 325 
compared with control mice [17]. Interestingly, glucose tolerance of SA-Ptp1b
-/-
 mice 326 
returned to the responsiveness measured in these mice on chow diet, suggesting a reversal in 327 
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glucose intolerance that was caused by 12-weeks of HFD-feeding prior to inhibition of 328 
hepatic Ptp1b. Furthermore, SA-Ptp1b
-/-
 mice exhibited significantly lower blood glucose 329 
levels in response to a pyruvate bolus, suggesting an increased ability of insulin to suppress 330 
hepatic gluconeogenesis. Consistent with these physiological data and our previous studies 331 
using Alb-Ptp1b
-/-
 mice, we observed increased insulin-induced dephosphorylation of 332 
glycogen synthase and decreased expression of the gluconeogenic gene Pepck in livers of SA-333 
Ptp1b
-/-
 mice, in the absence of changes in liver glycogen content [17]. This suggests that SA-334 
Ptp1b
-/-
 mice have an improved gluconeogenic response, efficiently shutting down hepatic 335 
glucose production compared to control mice.  336 
    It is interesting to note that in our experiment insulin treatment of the control mice led to 337 
increased phosphorylation of GS, whilst in the SA-Ptp1b
-/-
 mice it led to the expected 338 
dephosphorylation. At the moment, it is unclear how hepatic PTP1B inhibition affects GS 339 
phosphorylation independently of its effects on the insulin receptor; however, PTP1B has 340 
been shown to regulate PP2A activation [36] as well as regulate hepatic Srebp1 gene 341 
expression through the PP2A axis [37], which may then affect GS hepatic phosphorylation 342 
state [38]. This is currently under investigation in our lab, but is consistent with data from 343 
Ptp1b
-/-
 immortalised cells treated with insulin, which were also shown to exhibit enhanced 344 
dephosphorylation of the S641 site on GS [39].  345 
    Liver-Ptp1b deletion has previously been shown to decrease serum triglyceride with lower 346 
expression of lipogenic genes [17]. This suggests that PTP1B knockdown may be a suitable 347 
therapy for NAFLD, which is characterised by increased hepatic lipid accumulation and 348 
insulin resistance. A recent study showed that the dietary supplement, curcumin, inhibits 349 
PTP1B and prevents hepatic steatosis in fructose-fed rats, providing support behind this 350 
notion [40]. Here, we demonstrate that Ptp1b knockdown in obese and diabetic mice results 351 
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in lower liver triglyceride levels associated with decreased expression of Pparγ, which has 352 
been found to be elevated in fatty livers [41].  353 
    Interestingly, a paradoxical phenotype was previously observed in Alb-Ptp1b
-/-
 mice; they 354 
displayed increased hepatic insulin signalling and decreased expression levels of hepatic 355 
Srebp1c, Fas and other lipogenic markers [16, 17]. It is suggested that PTP1B may affect 356 
Srebp1 gene expression via a non-insulin signalling pathway in the liver involving effects on 357 
PP2A activity [23, 37]. No differences were noted in Srebp1a, Srebp1c or Fas in the current 358 
study; it may be that a 50% PTP1B knockdown is not sufficient to measure detectable 359 
changes or may be due to the differences in timing of the Ptp1b deletion. 360 
    We have previously shown that Alb-Ptp1b
-/-
 mice, which delete hepatic-Ptp1b from birth, 361 
are protected against HFD-induced hepatic ER stress [17]. Consistent with this, SA-Ptp1b
-/-
 362 
mice also have decreased phosphorylation levels of PERK, eIF2α and JNK2, indicating that 363 
~50% knockdown of Ptp1b can temporally improve ER stress. Moreover, in the absence of 364 
changes in the classical IR signalling, this study suggests that improvements in lipid 365 
homeostasis observed with hepatic-Ptp1b knockdown, may be due to decreased ER stress 366 
response signalling.  367 
    SA-Ptp1b
-/-
 mice displayed significantly lower fed and fasted leptin levels 4-weeks after 368 
Ptp1b knockdown was induced. This is the first time that Ptp1b knockdown in the liver has 369 
been reported to affect circulating leptin levels. PTP1B has been well documented to regulate 370 
leptin receptor signalling [18, 42]. However, leptin action in the liver remains inconclusive. 371 
Diet-induced obese rats have been shown to exhibit decreased hepatic levels of leptin 372 
receptor transcripts [43, 44]. Moreover, leptin-treatment of wild type mice led to increased 373 
mRNA expression of several isoforms of the leptin receptor, including the long form of the 374 
receptor (ObRb) [45], suggesting that the liver may be an important site of leptin action. 375 
Furthermore, over-expression of PTP1B in the liver was shown to restrict the ability of leptin 376 
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to lower blood glucose levels and suppress food intake [46]. It was suggested that strategies 377 
aimed at suppressing PTP1B specifically in the liver could improve both hepatic insulin and 378 
leptin sensitivity [46]. Revealing the mechanism(s) behind our current observations should 379 
form part of future studies. 380 
    Overall, tissue-specific knockout/knockdown studies of PTP1B have revealed key roles for 381 
brain-, liver- and muscle-PTP1B in the regulation of global energy and glucose homeostasis. 382 
We now demonstrate that liver-Ptp1b knockdown does not only prevent, but can reverse 383 
established insulin resistance and glucose intolerance and also decrease ER stress and fat 384 
accumulation in the liver in the obese and insulin resistant states. Inhibition of PTP1B 385 
remains a promising potential therapy for type 2 diabetes treatment as well as a potential 386 
protection against the development of NAFLD. 387 
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Table 1. Lipid and glucose metabolism gene expression in liver and epididymal WAT. 533 
Data are presented as fold change relative to Ptp1b
fl/fl 
group. Data represented as mean ± 534 
SEM. Data were analyzed using two-tailed Student’s t test (*P < 0.05). 535 
Parameter 
Ptp1b
fl/fl  
(n = 6-7) 
SA-Ptp1b
-/- 
(n = 6-8)
 
P value 
Liver metabolism   
 
Fas 1.0 ± 0.06 1.0 ± 0.23 
 
0.983 
Srebp1c 1.0 ± 0.11 1.4 ± 0.24 0.155 
Srebp1a 1.0 ± 0.22 1.3 ± 0.22 0.380 
Srebp2 1.0 ± 0.20 1.1 ± 0.23 0.751 
Hmgcs1 1.0 ± 0.14  1.9 ± 0.32* 0.023 
Pparγ 1.0 ± 0.12   0.6 ± 0.08* 0.023 
Pparα 1.0 ± 0.14 0.8 ± 0.12 0.307 
Pgc1α 1.0 ± 0.13 0.7 ± 0.07 0.056 
Pepck 1.0 ± 0.14   0.6 ± 0.05* 0.018 
G6p 1.0 ± 0.26 0.7 ± 0.15 0.289 
 
Liver ER stress    
 
Bip 1.0 ± 0.08 0.9 ± 0.08 
 
0.317 
Grp94 1.0 ± 0.12   0.6 ± 0.10* 0.043 
Chop 1.0 ± 0.05 1.1 ± 0.22 0.667 
Xbp Spliced 1.0 ± 0.13 1.3 ± 0.16 0.241 
Xbp Total 1.0 ± 0.08 1.2 ± 0.15 0.268 
Atf4 1.0 ± 0.06 1.1 ± 0.09 0.296 
 
Adipose tissue metabolism   
 
Fas 1.0 ± 0.11 0.8 ± 0.14 
 
0.303 
Srebp1c 1.0 ± 0.20 1.2 ± 0.21 0.605 
Srebp1a 1.0 ± 0.15 1.1 ± 0.13 0.565 
Pparγ 1.0 ± 0.10 0.9 ± 0.16 0.622 
Pparα 1.0 ± 0.27 1.2 ± 0.43 0.775 
Hsl 1.0 ± 0.17 0.9 ± 0.13 0.673 
Atgl 1.0 ± 0.17 0.7 ± 0.11 0.150 
Rbp4 1.0 ± 0.15 0.8 ± 0.19 0.461 
Leptin 1.0 ± 0.27 0.9 ± 0.29 0.820 
Adipoq 1.0 ± 0.15 0.6 ± 0.20 0.185 
Resistin 1.0 ± 0.23 0.9 ± 0.23 0.792 
Glut4 1.0 ± 0.17 0.8 ± 0.12 0.315 
Pepck 1.0 ± 0.17 0.7 ± 0.19 0.272 
F480 1.0 ± 0.44 0.7 ± 0.38 0.652 
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Table 2. Serum glucose parameters IL-6, MCP-1 and Resistin. 536 
Parameter Ptp1b
fl/fl
 (n = 6) SA-Ptp1b
-/-
 (n = 6) 
IL-6 Pre (pmol/l) 1.04 ± 0.39 0.65 ± 0.18 
IL-6 Post 4 (pmol/l) 0.31 ± 0.08 0.71 ± 0.32 
IL-6 Post 12 (pmol/l) 1.43 ± 0.43 0.5 ± 0.07† 
MCP-1 Pre (pmol/l) 1.53 ± 0.1 1.27 ± 0.26 
MCP-1 Post 4 (pmol/l) 0.64 ± 0.26 2.82 ± 0.63* 
MCP-1 Post 12 (pmol/l) 1.17 ± 0.47 1.81 ± 0.52 
Resistin Pre (pmol/l) 108.13 ± 21.47 83.28 ± 15.55 
Resistin Post 4 (pmol/l) 102.38 ± 14.18 81.90 ± 22.28 
Resistin Post 12 (pmol/l) 77.04 ± 17.38 79.68 ± 13.53 
Data represented as mean ± SEM. Data were analyzed using one-way ANOVA with Tukey’s 537 
multiple comparison post-tests (*P < 0.05; † represents P = 0.059).  538 
 539 
FIGURE LEGENDS  540 
Figure 1. Body weight and Ptp1b knockdown/activity. a: Body weight of HFD-fed SA-541 
Ptp1b
-/-
 (n = 8) and HFD-fed Ptp1b
fl/fl
 control mice (n = 9). Experimental design and timings 542 
of tamoxifen treatment also displayed. b: PTP1B knockdown 4-weeks post-tamoxifen (n = 4-543 
7). c: PTP1B knockdown 12-weeks post-tamoxifen (n = 4-7). d: PTP1B activity 12-weeks 544 
post-tamoxifen. HFD-fed Ptp1b
fl/fl
 control mice n = 8, HFD-fed SA-Ptp1b
-/-
 mice n = 8 and 545 
HFD-fed Alb-Ptp1b
-/- 
mice n = 4. Data are represented as mean ± SEM. White bars/circles, 546 
Ptp1b
fl/fl
; black bars/circles SA-Ptp1b
-/-
; grey bars Alb-Ptp1b
-/-
. Data were analyzed by one-547 
tailed or two-tailed Student’s t test (*P < 0.05; **P < 0.01; † represents P = 0.054).  548 
 549 
Figure 2. Inducible liver-specific Ptp1b knockdown improves glucose homeostasis. a: 550 
Glucose tolerance test (GTT) of both groups on chow diet prior to tamoxifen treatment. b: 551 
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GTT of both groups on HFD for 8 weeks prior to tamoxifen treatment. c: GTT of both groups 552 
on HFD at 3 weeks after tamoxifen treatment. d: Area under the curve of GTT's. e: Pyruvate 553 
tolerance test of both groups on HFD 12 weeks after tamoxifen treatment. f: Fed serum 554 
glucose levels. g: Fasted serum glucose levels. h: Fed serum insulin levels. i: Fasted serum 555 
insulin levels. j: HOMA-IR. SA-Ptp1b
-/-
 and Ptp1b
fl/fl
 control groups are indicated in the 556 
figures. For all experiments n = 8 for HFD-fed SA-Ptp1b
-/-
 mice and n = 9 for HFD-fed 557 
Ptp1b
fl/fl
 control mice. Data are represented as mean ± SEM. White bars/circles, Ptp1b
fl/fl
; 558 
black bars/circles SA-Ptp1b
-/-
. Data were analyzed by repeated measures two-way ANOVA 559 
with Bonferroni multiple comparisons post-tests, one-way ANOVA with Tukey’s multiple 560 
comparison post-tests or two-tailed Student’s t test, where appropriate (*P < 0.05). 561 
 562 
Figure 3. Lipid homeostasis is improved with inducible liver-specific Ptp1b knockdown. 563 
a: Hematoxylin and eosin staining of livers b: Liver triglyceride assay from HFD-fed SA-564 
Ptp1b
-/-
 mice (SA) and HFD-fed Ptp1b
fl/fl
 control mice (FL). c: Alanine aminotransferase 565 
activity assay. d: Fed serum free fatty acid assay. e: Fasted serum free fatty acid assay. f: Fed 566 
serum triglyceride assay. g: Fasted serum triglyceride assay. h: Fed circulating leptin assay. i: 567 
Fasted circulating leptin assay. SA-Ptp1b
-/-
 and Ptp1b
fl/fl
 control groups are indicated in the 568 
figures. For all experiments n = 8 for HFD-fed SA-Ptp1b
-/-
 mice and n = 9 for HFD-fed 569 
Ptp1b
fl/fl
 control mice. Data are represented as mean ± SEM. White bars, Ptp1b
fl/fl
; black bars 570 
SA-Ptp1b
-/-
. Data were analyzed by one-way ANOVA with Tukey’s multiple comparison 571 
post-tests or two-tailed Student’s t test, where appropriate (*P < 0.05). 572 
 573 
Figure 4. Inducible liver-specific Ptp1b knockdown improves suppression of hepatic 574 
gluconeogenesis. a: Liver insulin signalling 4-weeks post-tamoxifen in HFD-fed Ptp1b
fl/fl
 575 
and HFD-fed SA-Ptp1b
-/-
 mice after injection with saline or insulin (10 mU/g). b: Liver 576 
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insulin signalling 12-weeks post-tamoxifen in HFD-fed Ptp1b
fl/fl
 and HFD-fed SA-Ptp1b
-/-
 577 
mice after injection with saline or insulin (10 mU/g). c: Quantification of glycogen synthase 578 
immunoblot 4-weeks post-tamoxifen. HFD-fed Ptp1b
fl/fl
 control mice n = 7 (3 saline/4 579 
insulin) and HFD-fed SA-Ptp1b
-/-
 n = 10 (3 saline/7 insulin). d: Quantification of glycogen 580 
synthase immunoblot 12-weeks post-tamoxifen. HFD-fed Ptp1b
-fl/fl
 control mice n = 7 (3 581 
saline/4 insulin) and HFD-fed SA-Ptp1b
-/-
 n = 10 (3 saline/7 insulin). e: Liver IR 582 
phosphorylation by immunoprecipitation 12-weeks post-tamoxifen. HFD-fed Ptp1b
fl/fl
 control 583 
mice n = 6 (2 saline/4 insulin) and HFD-fed SA-Ptp1b
-/-
 n = 6 (2 saline/4 insulin). f Muscle 584 
insulin signalling 12-weeks post-tamoxifen. g: Epididymal WAT insulin signalling 12-weeks 585 
post-tamoxifen. HFD-fed Ptp1b
fl/fl
 control mice n = 7 (3 saline/4 insulin) and HFD-fed SA-586 
Ptp1b
-/-
 n = 7 (3 saline/4 insulin). Data are represented as mean ± SEM. White bars, Ptp1b
fl/fl
; 587 
black bars SA-Ptp1b
-/-
. Data were analyzed by one-way ANOVA with Tukey’s multiple 588 
comparison post-tests or two-tailed Student’s t test, where appropriate (*P < 0.05). 589 
 590 
Figure 5. Inducible liver-specific Ptp1b knockdown reduces ER stress. a: Representative 591 
blot of liver ER stress signalling 12-weeks post-tamoxifen in HFD-fed Ptp1b
fl/fl
 and HFD-fed 592 
SA-Ptp1b
-/-
 mice. b-e: Quantification of pPERK, peIF2α, pJNK2 and pJNK1 immunoblots. 593 
HFD-fed Ptp1b
fl/fl
 control mice n = 7 and HFD-fed SA-Ptp1b
-/-
 n = 10. Data are represented 594 
as mean ± SEM. White bars, Ptp1b
fl/fl
; black bars SA-Ptp1b
-/-
. Data were analyzed by two-595 
tailed Student’s t test (*P < 0.05; **P < 0.01; ***P < 0.001). 596 
